Last reviewed · How we verify
Low-Dose Glucagon
Low-Dose Glucagon is a Glucagon receptor agonist Small molecule drug developed by Steno Diabetes Center Copenhagen. It is currently FDA-approved for Acute hypoglycemia in patients with diabetes mellitus.
Low-dose glucagon activates glucagon receptors to stimulate hepatic glucose output and counteract hypoglycemia in diabetes patients.
Low-Dose Glucagon has been studied in clinical trials for conditions such as Type 2 Diabetes Mellitus, Hypoglycemia, and Type 1 Diabetes. The mechanism of Low-Dose Glucagon is related to glucagon-like peptide-1 agonism, as seen in studies involving GLP-1 agonists like Semaglutide.
At a glance
| Generic name | Low-Dose Glucagon |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Glucagon receptor agonist |
| Target | Glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glucagon is a hormone that binds to glucagon receptors on hepatic cells, triggering glycogenolysis and gluconeogenesis to raise blood glucose levels. At low doses, it provides rapid glucose elevation with reduced gastrointestinal side effects compared to standard glucagon doses. This mechanism makes it suitable for treating acute hypoglycemic episodes in diabetic patients, particularly those on insulin therapy.
Approved indications
- Acute hypoglycemia in patients with diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Headache
- Hyperglycemia (rebound)
Key clinical trials
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (PHASE4)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- The Postprandial Hypo-Avoid Study (PHASE4)
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) (PHASE2)
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity (PHASE2)
- Glucagon Resistance in Patients With MASLD and T2DM (NA)
- Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes (NA)
- Bariatric Surgery Combined With GLP-1 Receptor Agonists Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-Dose Glucagon CI brief — competitive landscape report
- Low-Dose Glucagon updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI
Frequently asked questions about Low-Dose Glucagon
What is Low-Dose Glucagon?
How does Low-Dose Glucagon work?
What is Low-Dose Glucagon used for?
Who makes Low-Dose Glucagon?
What drug class is Low-Dose Glucagon in?
What development phase is Low-Dose Glucagon in?
What are the side effects of Low-Dose Glucagon?
What does Low-Dose Glucagon target?
Related
- Drug class: All Glucagon receptor agonist drugs
- Target: All drugs targeting Glucagon receptor (GCGR)
- Manufacturer: Steno Diabetes Center Copenhagen — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Acute hypoglycemia in patients with diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing